Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA

Oncology Reports

Volumn 25, Issue 3, 2011, Pages 803-808

  Chen, Rong Xin ^a,b   Xia, Yun Hong ^a,b   Xue, Tong Chun ^a,b   Zhang, Hong ^c   Ye, Sheng Long ^a,b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotides; Hepatocellular carcinoma; Metastasis; Osteopontin

Indexed keywords

2' O METHOXYETHYLRIBOSE; ANTISENSE OLIGONUCLEOTIDE; GELATINASE A; MESSENGER RNA; OSTEOPONTIN; OSTEOPONTIN ANTISENSE OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID; RIBOSE; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN HCCLM6; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; XENOGRAFT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OSTEOPONTIN; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79551602459     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1116     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, Ji XN, Liu H, Xia JL, Wu ZQ, Fan J, Ma ZC, Zhou XD, Lin ZY and Liu KD: A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 187-196, 2004.
3. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY and Wang XW: Predicting hepatitis virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9: 416-423, 2003.
4. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF and Yeatman TJ: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10: 184-190, 2004.
5. Shevde LA, Das S, Clark DW and Samant RS: Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 10: 71-81, 2010.
6. Wai PY and Kuo PC: Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27: 103-118, 2008.
7. Johnston NI, Gunasekharan VK, Ravindranath A, O'Connell C, Johnston PG and El-Tanani MK: Osteopontin as a target for cancer therapy. Front Biosci 13: 4361-4372, 2008.
8. Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL, Liu YK and Tang ZY: Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol 130: 460-468, 2004.
9. Rittling SR and Chambers AF: Role of osteopontin in tumour progression. Br J Cancer 90: 1877-1881, 2004.
10. Das R, Mahabeleshwar GH and Kundu GC: Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278: 28593-28606, 2003.
11. Das R, Philip S, Mahabeleshwar GH, Bulbule A and Kundu GC: Osteopontin: Its role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life 57: 441-447, 2005.
12. Robertson BW and Chellaiah MA: Osteopontin induces beta-catenin signaling through activation of Akt in prostate cancer cells. Exp Cell Res 316: 1-11, 2010.
13. Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, Travali S, Stivala F, Canevari S and Libra M: Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 14: 7470-7480, 2008.
14. Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ, Ren N and Qin LX: Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 48: 1834-1842, 2008.
15. Mi Z, Guo H, Wai PY, Gao C and Kuo PC: Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis 27: 1134-1145, 2006.
16. Oh YK and Park TG: siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 61: 850-862, 2009.
17. Tamm I, Dorken B and Hartmann G: Antisense therapy in oncology: new hope for an old idea? Lancet 358: 489-497, 2001.
18. Wacheck V and Zangemeister-Wittke U: Antisense molecules for targeted cancer therapy. Crit Rev Oncol Hematol 59: 65-73, 2006.
19. But DY, Lai CL and Yuen MF: Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 14: 1652-1656, 2008.
20. Yu XX, Murray SF, Pandey SK, Booten SL, Bao D, Song XZ, Kelly S, Chen S, McKay R, Monia BP and Bhanot S: Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42: 362-371, 2005.